NCT01423825View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
HIV Infections
Interventions
BIOLOGICAL

Sub C gp140 Vaccine

100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid

BIOLOGICAL

MF59C.1 Adjuvant

MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.

OTHER

Sodium chloride

Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo

Trial Locations (4)

1864

Soweto HVTN CRS, Johannesburg

7750

Emavundleni CRS, Cape Town

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

02215-4302

Fenway Health (FH) CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01423825 - Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102) | Biotech Hunter | Biotech Hunter